These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27642756)

  • 1. On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).
    Candia M; Kratzer B; Pickl WF
    Int Arch Allergy Immunol; 2016; 170(4):211-233. PubMed ID: 27642756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.
    Carson RT; Vignali KM; Woodland DL; Vignali DA
    Immunity; 1997 Sep; 7(3):387-99. PubMed ID: 9324359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell recognition of self and altered self antigens.
    Nicholson LB; Kuchroo VK
    Crit Rev Immunol; 1997; 17(5-6):449-62. PubMed ID: 9419432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor.
    Sant'Angelo DB; Robinson E; Janeway CA; Denzin LK
    Eur J Immunol; 2002 Sep; 32(9):2510-20. PubMed ID: 12207335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands.
    Kersh GJ; Allen PM
    J Exp Med; 1996 Oct; 184(4):1259-68. PubMed ID: 8879197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected].
    Boniface JJ; Rabinowitz JD; Wülfing C; Hampl J; Reich Z; Altman JD; Kantor RM; Beeson C; McConnell HM; Davis MM
    Immunity; 1998 Oct; 9(4):459-66. PubMed ID: 9806632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possibilities and limitations in the rational design of modified peptides for T cell mediated immunotherapy.
    de Haan EC; Moret EE; Wagenaar-Hilbers JP; Liskamp RM; Wauben MH
    Mol Immunol; 2005 Feb; 42(3):365-73. PubMed ID: 15589325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-step binding mechanism for T-cell receptor recognition of peptide MHC.
    Wu LC; Tuot DS; Lyons DS; Garcia KC; Davis MM
    Nature; 2002 Aug; 418(6897):552-6. PubMed ID: 12152083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TCR-induced alteration of primary MHC peptide anchor residue.
    Madura F; Rizkallah PJ; Legut M; Holland CJ; Fuller A; Bulek A; Schauenburg AJ; Trimby A; Hopkins JR; Wells SA; Godkin A; Miles JJ; Sami M; Li Y; Liddy N; Jakobsen BK; Loveridge EJ; Cole DK; Sewell AK
    Eur J Immunol; 2019 Jul; 49(7):1052-1066. PubMed ID: 31091334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.
    Thomas S; Xue SA; Bangham CR; Jakobsen BK; Morris EC; Stauss HJ
    Blood; 2011 Jul; 118(2):319-29. PubMed ID: 21606483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen.
    Ehrich EW; Devaux B; Rock EP; Jorgensen JL; Davis MM; Chien YH
    J Exp Med; 1993 Aug; 178(2):713-22. PubMed ID: 8393480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.
    Spear TT; Wang Y; Smith TW; Simms PE; Garrett-Mayer E; Hellman LM; Baker BM; Nishimura MI
    Mol Ther; 2018 Apr; 26(4):996-1007. PubMed ID: 29503203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous altered peptide ligands can affect peripheral T cell responses.
    Vidal K; Hsu BL; Williams CB; Allen PM
    J Exp Med; 1996 Apr; 183(4):1311-21. PubMed ID: 8666889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-Layer-based analysis of peptide-MHC interaction: in silico prediction, peptide binding affinity and T cell activation in a relevant allergen-specific model.
    Knapp B; Omasits U; Bohle B; Maillere B; Ebner C; Schreiner W; Jahn-Schmid B
    Mol Immunol; 2009 May; 46(8-9):1839-44. PubMed ID: 19232439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological events underlying the induction of T cell non-responsiveness.
    Larché M; Hoyne G; Lake R; Lamb JR
    Int Arch Allergy Immunol; 1994 Jul; 104(3):211-5. PubMed ID: 8032232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular components of T-cell recognition.
    Jorgensen JL; Reay PA; Ehrich EW; Davis MM
    Annu Rev Immunol; 1992; 10():835-73. PubMed ID: 1591005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases.
    Sauer EL; Cloake NC; Greer JM
    Int Rev Immunol; 2015; 34(6):460-85. PubMed ID: 25970132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the cognate peptide-MHC target of T cell receptors using molecular modeling and force field scoring.
    Lanzarotti E; Marcatili P; Nielsen M
    Mol Immunol; 2018 Feb; 94():91-97. PubMed ID: 29288899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex.
    Adams JJ; Narayanan S; Liu B; Birnbaum ME; Kruse AC; Bowerman NA; Chen W; Levin AM; Connolly JM; Zhu C; Kranz DM; Garcia KC
    Immunity; 2011 Nov; 35(5):681-93. PubMed ID: 22101157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation.
    Germain RN; Stefanová I
    Annu Rev Immunol; 1999; 17():467-522. PubMed ID: 10358766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.